PUBLISHER: The Business Research Company | PRODUCT CODE: 1750996
PUBLISHER: The Business Research Company | PRODUCT CODE: 1750996
Familial Mediterranean Fever Pharmaceuticals Global Market Report 2025
Familial Mediterranean fever (FMF) pharmaceuticals refer to medications used to manage and treat FMF, a genetic disorder marked by recurrent episodes of fever and inflammation, often affecting the abdomen, chest, and joints. The primary goal of these medications is to reduce the frequency and severity of attacks and prevent long-term complications such as amyloidosis.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main pharmaceuticals used in the treatment of familial Mediterranean fever include colchicine, interleukin-1 inhibitors, and anti-IL-6 drugs. Colchicine is a medication that helps reduce inflammation and prevent flare-ups in conditions such as gout and other inflammatory disorders. It can be administered both orally and via injection and is utilized by various end users, including hospitals, clinical diagnostic laboratories, and other healthcare facilities.
The familial mediterranean fever pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides familial mediterranean fever pharmaceuticals market statistics, including familial mediterranean fever pharmaceuticals industry global market size, regional shares, competitors with a familial mediterranean fever pharmaceuticals market share, detailed familial mediterranean fever pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the familial mediterranean fever pharmaceuticals industry. This familial mediterranean fever pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The familial mediterranean fever pharmaceuticals market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.74 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth observed in the historic period can be attributed to factors such as the increasing prevalence of the disease, higher migration rates, a growing geriatric population, a rise in genetic abnormalities within the MEFV gene, and an increase in genetic mutations.
The familial mediterranean fever pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $2.15 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth projected for the forecast period can be attributed to factors such as the increased adoption of advanced cancer therapeutic options, growing interest in gene therapy and biologics, a rise in the use of advanced therapies, higher utilization of effective medications, and the widespread adoption of supportive therapies. Key trends during this period include advancements in treatment methods, the introduction of new drug classes, collaboration between academic institutions, research organizations, and pharmaceutical companies, the adoption of new therapeutics, and developments in technology.
The growing adoption of gene therapy is expected to significantly boost the growth of the familial Mediterranean fever (FMF) pharmaceuticals market. Gene therapy is a medical approach that alters or replaces defective genes to treat or prevent diseases at the genetic level. The rise in gene therapy is fueled by advancements in genetic engineering, which allow for precise targeting and correction of genetic disorders, offering potential cures for conditions previously considered untreatable. In the case of familial Mediterranean fever (FMF), gene therapy targets the root cause mutations in the MEFV (Mediterranean fever) gene, potentially offering a long-term or permanent cure rather than merely managing symptoms. For example, in July 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, marking a 25% increase from the previous quarter. As a result, the rise in gene therapy is driving the growth of the FMF pharmaceuticals market.
Leading companies in the familial Mediterranean fever (FMF) pharmaceuticals market are focusing on developing advanced treatments, including cost-effective generic alternatives, as well as exploring novel biologics and gene therapies. A cost-effective generic alternative is a lower-cost version of a branded drug that retains the same active ingredients, dosage, safety, and effectiveness. For example, in January 2022, Camber Pharmaceuticals Inc., a US-based pharmaceutical manufacturing company, introduced generic Colcrys (colchicine) tablets, expanding its product portfolio. These tablets are used to treat and prevent FMF in both adults and children aged four and older, as well as for managing gout flare-ups. The tablets, available in 0.6 mg strength, come in 30- and 100-count bottles. This launch aligns with Camber's commitment to providing high-quality, affordable generic medications to improve patient care.
In January 2024, Swedish Orphan Biovitrum AB (Sobi), a Sweden-based manufacturer of Interleukin-1 inhibitors, entered into a partnership with Acino International AG. This partnership grants Acino the exclusive rights to distribute Sobi's specialized rare disease treatments in Kazakhstan, thereby expanding access to innovative therapies. Acino International AG, a Swiss-based pharmaceutical company, specializes in the development, manufacturing, and distribution of high-quality generic and specialty medicines.
Major players in the familial mediterranean fever pharmaceuticals market are Merck & Co. Inc., Bristol Myers Squibb, Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Swedish Orphan Biovitrum AB (Sobi), Granules Pharmaceuticals Inc., Sanmar Group, Indena S.p.A., Harman Finochem, Camber Pharmaceuticals Inc., R-Pharm Group, Alchem International, AdvaCare Pharma USA LLC, ViennaLab Diagnostics GmbH, Honour Lab Ltd., Vital Laboratories Pvt. Ltd., Enomark Biotech Pvt. Ltd., Gonane Pharma, Ennature Biopharma.
Middle East was the largest region in the familial mediterranean fever pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in familial mediterranean fever pharmaceuticals report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the familial mediterranean fever pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The familial mediterranean fever pharmaceuticals market consists of sales of NSAIDs, corticosteroids, immunosuppressants, disease-modifying antirheumatic drugs, and pain management medications used to manage inflammation and prevent complications in familial mediterranean fever patients. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Familial Mediterranean Fever Pharmaceuticals Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on familial mediterranean fever pharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for familial mediterranean fever pharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The familial mediterranean fever pharmaceuticals market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Type: Colchicine; Interleukin-1 Inhibitors; Anti-IL-6 Drugs
- 2) By Route Of Administration: Oral; Injectable
- 3) By End Users: Hospitals; Clinical Diagnostic Laboratories; Other End Users
- Subsegments:
- 1) By Colchicine: Oral Colchicine; Intravenous Colchicine
- 2) By Interleukin-1 Inhibitors: Anakinra; Canakinumab; Rilonacept
- 3) By Anti-IL-6 Drugs: Tocilizumab; Sarilumab; Siltuximab
- Companies Mentioned: Merck & Co. Inc.; Bristol Myers Squibb; Novartis International AG; Takeda Pharmaceutical Company Limited; Amgen Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Familial Mediterranean Fever Pharmaceuticals Market Characteristics
3. Familial Mediterranean Fever Pharmaceuticals Market Trends And Strategies
4. Familial Mediterranean Fever Pharmaceuticals Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Familial Mediterranean Fever Pharmaceuticals Growth Analysis And Strategic Analysis Framework
- 5.1. Global Familial Mediterranean Fever Pharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Familial Mediterranean Fever Pharmaceuticals Market Growth Rate Analysis
- 5.4. Global Familial Mediterranean Fever Pharmaceuticals Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Familial Mediterranean Fever Pharmaceuticals Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Familial Mediterranean Fever Pharmaceuticals Total Addressable Market (TAM)
6. Familial Mediterranean Fever Pharmaceuticals Market Segmentation
- 6.1. Global Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Colchicine
- Interleukin-1 Inhibitors
- Anti-IL-6 Drugs
- 6.2. Global Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injectable
- 6.3. Global Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinical Diagnostic Laboratories
- Other End Users
- 6.4. Global Familial Mediterranean Fever Pharmaceuticals Market, Sub-Segmentation Of Colchicine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Colchicine
- Intravenous Colchicine
- 6.5. Global Familial Mediterranean Fever Pharmaceuticals Market, Sub-Segmentation Of Interleukin-1 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anakinra
- Canakinumab
- Rilonacept
- 6.6. Global Familial Mediterranean Fever Pharmaceuticals Market, Sub-Segmentation Of Anti-IL-6 Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tocilizumab
- Sarilumab
- Siltuximab
7. Familial Mediterranean Fever Pharmaceuticals Market Regional And Country Analysis
- 7.1. Global Familial Mediterranean Fever Pharmaceuticals Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Familial Mediterranean Fever Pharmaceuticals Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market
- 8.1. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Familial Mediterranean Fever Pharmaceuticals Market
- 9.1. China Familial Mediterranean Fever Pharmaceuticals Market Overview
- 9.2. China Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Familial Mediterranean Fever Pharmaceuticals Market
- 10.1. India Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Familial Mediterranean Fever Pharmaceuticals Market
- 11.1. Japan Familial Mediterranean Fever Pharmaceuticals Market Overview
- 11.2. Japan Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Familial Mediterranean Fever Pharmaceuticals Market
- 12.1. Australia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Familial Mediterranean Fever Pharmaceuticals Market
- 13.1. Indonesia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Familial Mediterranean Fever Pharmaceuticals Market
- 14.1. South Korea Familial Mediterranean Fever Pharmaceuticals Market Overview
- 14.2. South Korea Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Familial Mediterranean Fever Pharmaceuticals Market
- 15.1. Western Europe Familial Mediterranean Fever Pharmaceuticals Market Overview
- 15.2. Western Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Familial Mediterranean Fever Pharmaceuticals Market
- 16.1. UK Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Familial Mediterranean Fever Pharmaceuticals Market
- 17.1. Germany Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Familial Mediterranean Fever Pharmaceuticals Market
- 18.1. France Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Familial Mediterranean Fever Pharmaceuticals Market
- 19.1. Italy Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Familial Mediterranean Fever Pharmaceuticals Market
- 20.1. Spain Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market
- 21.1. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market Overview
- 21.2. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Familial Mediterranean Fever Pharmaceuticals Market
- 22.1. Russia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Familial Mediterranean Fever Pharmaceuticals Market
- 23.1. North America Familial Mediterranean Fever Pharmaceuticals Market Overview
- 23.2. North America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Familial Mediterranean Fever Pharmaceuticals Market
- 24.1. USA Familial Mediterranean Fever Pharmaceuticals Market Overview
- 24.2. USA Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Familial Mediterranean Fever Pharmaceuticals Market
- 25.1. Canada Familial Mediterranean Fever Pharmaceuticals Market Overview
- 25.2. Canada Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Familial Mediterranean Fever Pharmaceuticals Market
- 26.1. South America Familial Mediterranean Fever Pharmaceuticals Market Overview
- 26.2. South America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Familial Mediterranean Fever Pharmaceuticals Market
- 27.1. Brazil Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Familial Mediterranean Fever Pharmaceuticals Market
- 28.1. Middle East Familial Mediterranean Fever Pharmaceuticals Market Overview
- 28.2. Middle East Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Familial Mediterranean Fever Pharmaceuticals Market
- 29.1. Africa Familial Mediterranean Fever Pharmaceuticals Market Overview
- 29.2. Africa Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Familial Mediterranean Fever Pharmaceuticals Market Competitive Landscape And Company Profiles
- 30.1. Familial Mediterranean Fever Pharmaceuticals Market Competitive Landscape
- 30.2. Familial Mediterranean Fever Pharmaceuticals Market Company Profiles
- 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Familial Mediterranean Fever Pharmaceuticals Market Other Major And Innovative Companies
- 31.1. Swedish Orphan Biovitrum AB (Sobi)
- 31.2. Granules Pharmaceuticals Inc.
- 31.3. Sanmar Group
- 31.4. Indena S.p.A.
- 31.5. Harman Finochem
- 31.6. Camber Pharmaceuticals Inc.
- 31.7. R-Pharm Group
- 31.8. Alchem International
- 31.9. AdvaCare Pharma USA LLC
- 31.10. ViennaLab Diagnostics GmbH
- 31.11. Honour Lab Ltd.
- 31.12. Vital Laboratories Pvt. Ltd.
- 31.13. Enomark Biotech Pvt. Ltd.
- 31.14. Gonane Pharma
- 31.15. Ennature Biopharma
32. Global Familial Mediterranean Fever Pharmaceuticals Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Familial Mediterranean Fever Pharmaceuticals Market
34. Recent Developments In The Familial Mediterranean Fever Pharmaceuticals Market
35. Familial Mediterranean Fever Pharmaceuticals Market High Potential Countries, Segments and Strategies
- 35.1 Familial Mediterranean Fever Pharmaceuticals Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Familial Mediterranean Fever Pharmaceuticals Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Familial Mediterranean Fever Pharmaceuticals Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250617_r34849_Familial_Mediterranean_Fever_Pharmaceuticals_GMR_2025
